On October 29
News list
1 Today's hot discussion
- National Medical Administration responded to "Artificial hematopoietic development ": If the requirements are met, review can be accelerated.
2 Economic Market
- 3 Kingsrui Biotechnology recently issued an announcement that Legend Bio's cell therapy CARVYKTI ( Sida Keolunsai ) achieved net sales in the third quarter this year in the third quarter US$355 million , and doubled its growth from 24 million in the second quarter. The total sales of in the two quarters was approximately RMB 570 million , exceeding market expectations. The Cyda Kiollens once again demonstrates strong market potential.
3 Illegal notification
- Another 207 pharmaceutical companies have had an accident ! Rectification, production suspension... (See the key to read in detail)
- abused power and relied on medical treatment to get medical treatment. two senior deans were arrested on the same day ! (See the key details for details)
4 The industry pays attention to
- 1.5 billion cepospores competition is fierce , and 3 other companies have been reviewed. (See the key details for details)
- On October 26, BMS released its 2022 third quarter report: Cell therapy abecma and Breyanzi achieved sales revenue of US$263 million and US$127 million in the first three quarters of this year. In Q3, abecma and Breyanzi had revenues of US$107 million and US$44 million respectively, while increased by 51% and 47% year-on-year compared with . Among them, Abecma is priced at US$438,000 per needle in the United States; Breyanzi is priced at US$410,300 per needle in the United States.
- The State Food and Drug Administration decided to uniformly revise the domperidone preparation (including domperidone tablets, domperidone dispersed tablets, domperidone oral disintegration tablets, domperidone capsules, domperidone suspension, domperidone maleate tablets) instruction manual . This revision adds 12 major adverse reactions to the system, as well as one precaution: use it with caution when children under 12 years old (especially infants), adolescents weighing less than 35 kg and adults, and monitor the adverse reactions closely when taking the medication.
5 Drug approval
- $2 billion antipsychotic drugs rose by 197%! Lizhao and Qilu attack . (See the key to read in detail)
- Kangyuan Class 1 new drug is coming ! Targeting the 170 billion market. (See the key details for details)
6 List released
- 2022 hospital market drug sales TOP3 released . (See the key details for details)
7 Changes in pharmaceutical companies
- can't sell! Zixin Pharmaceutical’s assets were auctioned, equity second time failed to auction ! (See the key details for details)
- Msody official recently issued a statement that the board election will be held by the current president and CEO Robert Davis (Robert M. Davis) as the chairman of the board of directors (Chairman) of Merck, and the appointment will take effect on December 1, 2022. Former chairman Kenneth Frazier will retire on November 30, 2022.
Focus on reading
Illegal notification
【There are another 207 pharmaceutical companies to get into trouble! Rectification, suspension of production...]On October 27, the Guangdong Provincial Drug Administration issued a notice on the results of drug business supervision, inspection and evaluation.The Notice Content of the
Notice states: According to the arrangement of the "2022 Provincial Drug Business and Utilization Unit Supervision and Inspection Plan" of the Guangdong Provincial Drug Administration and the Guangdong Provincial Drug Administration, the Provincial Drug Administration recently organized supervision and inspection of the following 199 drug business enterprises, and all the inspection results were basically in line with the requirements; the Provincial Bureau requires that these 199 pharmaceutical enterprises should strictly implement their main responsibilities in accordance with Article 32 of the "Drug Inspection Management Measures (Trial)" and rectify defective projects and promptly report the rectification implementation to the local market supervision and management department.
sorted out the list and found that is a group of well-known chain companies in the batch that need rectification, including Fersenius Pharmaceutical Device Logistics (Guangdong) Co., Ltd., Sinopharm Group Guangdong Medical Testing Co., Ltd., Shanghai Pharmaceutical Holdings Guangzhou Co., Ltd., Guangdong Huiyuantang Pharmaceutical Chain Co., Ltd., Guangdong Xinghetang Pharmaceutical Chain Co., Ltd., Guangzhou Baozhilin Pharmaceutical Chain Co., Ltd., Foshan Dasanlin Pharmaceutical Chain Co., Ltd., Shangyao Holdings (Meizhou) Co., Ltd., Dongguan Lemin Pharmaceutical Chain Co., Ltd., Jiangmen Dasanlin Pharmaceutical Co., Ltd., Guangdong Jianzhibao Pharmaceutical Chain Co., Ltd., Zhanjiang Yimin Pharmaceutical Chain Co., Ltd., Sinopharm Holdings Maoming Co., Ltd., Guangdong Xiuyangkang Pharmaceutical Chain Co., Ltd., Zhaoqing Minshengtang Pharmaceutical Group Co., Ltd.
There are also 8 companies in Anhui who have rectified the rectification, and one of them has stopped production of .
Coincidentally, on October 27, the Anhui Provincial Drug Administration issued an information notice on drug production supervision and inspection. The Notice Content of
shows that the Provincial Bureau has conducted routine inspections, rectification and re-examinations, and cause inspections on 45 pharmaceutical companies. Among them, 36 companies that meet the requirements, 8 companies that basically meet the requirements need to be rectified, namely Anhui Shuangke Pharmaceutical Co., Ltd. , Anhui Wellman Pharmaceutical Co., Ltd. , Wuhu Daorun Pharmaceutical Co., Ltd. Anhui Fengyuan Pharmaceutical Co., Ltd. , Anhui Huachen Pharmaceutical Co., Ltd., Wuhu Traditional Chinese Medicine Hospital, Tonglu Biopharmaceutical Co., Ltd., and Sinopharm Group Sanyi Pharmaceutical (Wuhu) Co., Ltd., most of them have been rectified at present; one company that does not meet the requirements is Anhui Urban Pharmaceutical Co., Ltd., and the provincial bureau has ordered it to suspend production, warn, and rectify.
[Abusing power and relying on medical treatment, the two senior deans were arrested on the same day! 】 After the national meeting, another group of medical system leaders were taken away for investigation...
On October 26, the Dongguan Municipal Commission for Discipline Inspection and Supervision released two review and investigation information, Directors and secretary of two -grade hospitals in the city were taken away on the same day.
1, former Party Secretary and President of Dongguan People's Hospital Mo Xinfa was expelled from the party despite serious violations of discipline and laws
3 days ago, with the approval of the Dongguan Municipal Party Committee, the Dongguan Municipal Commission for Discipline Inspection and Supervision filed a case for investigation and investigation of the serious violations of discipline and laws by Mo Xinfa, former Party Secretary and President of Dongguan People's Hospital.
After investigation, Mo Xinfa lost his ideals and beliefs, betrayed his original mission, was disloyal and dishonest to the Party, colluded with others and forged evidence to fight against organizational review; ignored the spirit of the Central Eight Regulations, accepted gifts and money in violation of regulations, accepted banquets and travel arrangements from service recipients; violated organizational principles, did not report personal matters in accordance with regulations, and was in the employment of employees. To seek profit for others; to violate the discipline of integrity and use power to seek personal gain for relatives; to abuse power and embezzle public funds for the purpose of illegal possession; to use position to embezzle public funds for personal use; to rely on medical treatment to engage in power and money transactions, to use position to seek benefits for others in medical equipment and drug procurement, engineering contracting, business convenience, etc., and to illegally accept huge amounts of property, but still do not know how to stop after retirement.
Mo Xinfa seriously violated the political discipline of the Party , organizational discipline , and integrity discipline, constituted serious violations of duty and suspected of corruption, embezzlement of public funds, bribery and bribery with influence, and did not restrain or stop after the 18th National Congress of the Communist Party of China. It is of serious nature and has a bad impact and should be dealt with seriously. In accordance with the relevant provisions of the " Disciplinary Punishment Regulations of the Communist Party of China ", " Supervision Law of the People's Republic of China ", "Administrative Punishment Law of the Public Officials of the People's Republic of China" and other relevant regulations, after research and approval by the Standing Committee of the Dongguan Municipal Commission for Discipline Inspection and submitted to the Dongguan Municipal Party Committee for approval, it was decided to expel Mo Xinfa from the Party; cancel his corresponding retirement benefits in accordance with the regulations; confiscate his illegal income; transfer his suspected criminal issues to the procuratorate for review and prosecution in accordance with the law, and transfer the property involved together.
2, former Party Secretary of Dongguan Binhai Bay Central Hospital Chen Guoming was expelled from the party and public office for serious violations of discipline and laws
3 days ago, with the approval of the Dongguan Municipal Party Committee, the Dongguan Municipal Commission for Discipline Inspection and Supervision filed a case for serious violations of discipline and laws by Chen Guoming, former Party Secretary of Dongguan Binhai Bay Central Hospital.
After investigation, Chen Guoming lost his ideals and beliefs, betrayed his original mission, violated the spirit of the Central Eight Regulations and the discipline of integrity, accepted gifts and cash in violation of regulations, and accepted banquets from the service recipients; violated organizational principles, and did not report personal matters in accordance with regulations; used his power for personal gain, used his power to seek benefits for others in medical device procurement, engineering construction projects, and business convenience, and illegally accepted huge amounts of property .
Chen Guoming seriously violated the party's organizational discipline and integrity discipline, constituted serious violations of duty and suspected of bribery. He did not restrain himself or stop after the 18th National Congress of the Communist Party of China, which is of serious nature and has a bad impact and should be dealt with seriously. In accordance with the "Regulations on Disciplinary Punishment of the Communist Party of China", "Supervision Law of the People's Republic of China", "Administrative Punishment Law of the People's Republic of China" and other relevant regulations, after research and approval by the Standing Committee of the Dongguan Municipal Commission for Discipline Inspection and submitted to the Dongguan Municipal Party Committee for approval, it was decided to expel Chen Guoming from the Party; the Dongguan Municipal Supervision Commission will expel him from public office; confiscate his illegal gains; transfer his suspected criminal issues to the procuratorate for review and prosecution in accordance with the law, and transfer the property involved together.
It is not difficult to see that the procurement of drugs, medical equipment, and consumables is still the core area of corruption in the medical system.
industry attention
[1.5 billion cepospores are fierce competition, add 3 review companies] On October 25, NMPA released a new batch of drug approval certificate documents to be received, among which multiple varieties of cefacxime are welcomed to be reviewed companies, involving Lijian Pharmaceutical , Shanghai Haihong Pharmaceutical and Sichuan Saizhuo Pharmaceutical , etc. So far, a total of 38 specifications of cefixime have passed the consistency evaluation, of which 13 product specifications were included in the 7th batch of centralized procurement.
Screenshot Source: NMPA official website
Cefixime is the first third generation oral cephalosporin. It is clinically suitable for bacterial infectious diseases caused by Streptococcus genus , Influenzae , etc. that are sensitive to cefixime. At present, a variety of dosage forms have been developed, including tablets, capsules, granules, and oral liquid agents. According to statistics from Yaorong Cloud, the hospital sales of cefixime in 2021 were 1.59 billion , of which the market share of in cefixime dispersed tablets has the highest (37.7%), followed by cefixime capsules and cefixime granules; from the perspective of enterprises, the Baiyunshan Pharmaceutical Factory accounts for as high as 64%.
Cefixime related preparations in hospital sales
Screenshot source: Yaorongyun National Hospital Sales Database
According to Yaorongyun Database, 4 varieties, including cefixime capsules, cefixime granules, cefixime tablets and cefixime dispersed tablets, have been reviewed by 5-11 companies, and have been included in the 7th batch of centralized procurement.No pharmaceutical companies have reviewed chewable tablets and dry suspensions. Only Shenzhen Lijian Pharmaceutical has submitted a supplementary application for consistency evaluation of the latter, which is still under review and approval.
Drug approval
【$2 billion antipsychotic drugs have risen by 197%! Lizhu , Qilu fierce attack] On October 27, the official website of the China National Medical Products Administration Drug Review Center (CDE) announced that Lizhu Group 4 generic chemical drug lurasidone hydrochloride tablets were applied for marketing and accepted . Lurasidone is originally developed by Sumitomo Pharmaceuticals. It is an atypical (second generation) antipsychotic drug developed by Sumitomo Pharmaceuticals. The global sales of the product exceeded the 2 billion mark in 2021, making it a "blockbuster drug".
Screenshot Source: CDE official website
In China, lurasidone obtained the marketing authorization of the National Drug Administration (NMPA) in January 2019 and was officially launched in China in September. In March 2021, it was officially included in the national medical insurance catalog. According to data from Yaorong Cloud, lurasidone's hospital sales exceeded 50 million yuan in the first half of 2022, and increased by 197% year-on-year, with a considerable expansion speed.
Lurasidone Hospital Sales
Screenshot: Yaorongyun National Hospital Sales Database
In addition to the original research, there are 4 domestic companies (Zhejiang Haizheng, Jiangsu Hausen, Zhengdatianqing , Yangtze River ), and generic drugs for lurasidone hydrochloride tablets with 3 specifications (80mg/40mg/20mg) have been approved. Among them, Zhejiang Haizheng Pharmaceutical won the first imitation. As more and more entrants are involved, the domestic market competition pattern of lurasidone will be broken.
In addition to Lizhu Group, according to Yaorong Cloud data, also has Changzhou Pharmaceutical, Qilu Pharmaceutical , Chongqing Yaoyou Pharmaceutical , Chenxin Pharmaceutical , Shijiazhuang Siyao and other pharmaceutical companies have submitted applications for the listing of lurasidone hydrochloride tablets to the CDE, and are all under review and approval.
This year, Lizhu Group also submitted a listing application for 2.4-category chemical injection esprazole sodium, 4-category chemical drug Bunanselin tablets, among which Bunanselin tablets have no generic drugs approved in China, and Lizhu is expected to win the first imitation.
[Kangyuan Class 1 new drug is coming! Targeting the 170 billion market] On October 27, the official website of CDE showed that Kangyuan Pharmaceutical 1 new drug KYS202002A injection clinical application was undertaken by , with the acceptance number CXSL2200544. KYS202002A is Kangyuan Pharmaceutical's first macromolecular biological drug, with an indication of multiple myeloma .
1 new drug KYS202002A injection is multiple myeloma, which is a plasma cell malignant tumor characterized by abnormal hyperplasia of bone marrow plasma cells accompanied by excessive generation of monoclonal immunoglobulin or light chain (M protein). The incidence of MM is high and it is the second common malignant tumor in the hematologic system.
The domestic tumor drug market has broad space. In recent years, with the increase in clinical drug demand and the acceleration of innovative drug approval and increased volume, anti-tumor and immunomodulators have become the first drug category in the hospital market. m Inside Network data shows that in 2021, the sales scale of terminal anti-tumor and immunomodulatory agents in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (hereinafter referred to as China's public medical institutions) exceeded 17 billion yuan , a year-on-year increase of 10.93%.
Terminal anti-tumor and immunomodulatory agents in public medical institutions in China
Sales (unit: 10,000 yuan)
Hotel: Mine.com Terminal competitive landscape of public medical institutions in China
In the field of anti-tumor and immunomodulatory agents, Kangyuan Pharmaceutical already has a small molecule innovative drug KY1701 tablet in the phase I clinical stage, which is used to treat advanced breast cancer.
Kangyuan Pharmaceutical is a leading domestic traditional Chinese medicine innovation enterprise. The company adheres to innovation-driven development, takes the development of traditional Chinese medicine as the main body, and actively plans to develop chemical drugs, biological drugs and other fields. In 2021, the company's R&D expenses were 499 million yuan, a year-on-year increase of 31.27%; in the first half of 2022, the R&D expenses were 277 million yuan, a year-on-year increase of 28.01%.
In addition to the products on the market, Kangyuan Pharmaceutical currently has 24 new Chinese medicine drugs and 6 small molecule innovative drugs in the clinical application stage and above. KYS202002A injection is Kangyuan Pharmaceutical's first large-molecular innovative drug to apply for clinical application, marking the company's entry into the field of biopharmaceuticals.
list release
[The TOP3 drugs sold in the hospital market will be released in 2022] 2022 is coming to an end. According to data from Zhongkang CMH, the total sales of Chinese hospital drug market in the first half of 2022 reached 452.9 billion yuan, a year-on-year decrease of 7.3%, mainly due to the decline in chemical drugs. The total number of hospital drug sales in Q2 2022 was 224.9 billion yuan, a year-on-year decrease of 10%. hospital drug market size has continued to decline for three consecutive quarters, and the decline rate has further expanded .
(Source: Zhongkang CMH)
So, what are the changes in the ranking of drugs sold in the hospital market? Let’s take a look together.
According to statistics from the National Hospital Sales Database of Yaorongyun, among the top 3 drugs sold in the hospital market in 2022H1, human blood albumin ranked first with sales of 7.376 billion yuan, a year-on-year increase of 14%. sodium chloride injection, cefoperidone sodium sulbactam sodium for injection followed closely.
(Source: Yaorongyun National Hospital Sales Database)
Pharmaceutical company changes
[can't sell! Zixin Pharmaceutical’s assets were auctioned and its equity failed to be sold for the second time! 】On October 27, Zixin Pharmaceutical issued two consecutive asset changes announcements.
sorted out the announcement and found that Zixin Pharmaceutical was unable to repay because it owed the bank 30 million yuan. Recently, the houses under its wholly-owned subsidiary Jilin Zixin Jingui Pharmaceutical Co., Ltd., with a real estate certificate number of Ji (2016) Tonghua City Real Estate No. 0002086 will be auctioned at 10:00 on November 1, 2022.
It is reported that Jilin Zixin Jingui Pharmaceutical Co., Ltd. was established on April 26, 2016 with a registered capital of 100 million yuan. It has been under construction since its establishment and has never been produced and operated. project under construction has been completely suspended since 2020.
In addition, Zixin Pharmaceutical's equity was previously auctioned by judicial authorities for the second time. Dunhua Kangping Investment Co., Ltd., the company's largest shareholder, holds 168598488 shares, accounting for 13.1639% of Zixin Pharmaceutical's total share capital. It was auctioned for the second time on Taobao Auction Network from 10:00 on October 19, 2022 to 10:00 on October 20, 2022, and was finally unsold again because no one bid. At present, all these shares and have been pledged and judicially frozen. If the shares held by Kangping Company are disposed of judicially, the company's control may change. Zixin Pharmaceutical has the risk of unstable control. Investors are advised to invest with caution.
Health knowledge
Many people feel panic and fearful when they hear mental disorder . In fact, mental disorders are not terrible. Like other physical diseases, they are a disease caused by the joint causes of biological-environment-psychology. Common mental illnesses include depression , anxiety disorder, etc.
——Health Times
Recommended reading
A hospital in Jiangsu was arrested for a 20-year-old female nurse; there is a possibility of radical cure in the late stage of cancer
! New treatment has been approved by the US FDA, AIDS may be cured
